ClinicalTrials.gg
CompletedNCT03500718Updated Feb 24, 2020

Changes in the Threshold of Electrically Evoked Compound Action Potential in Children Following Cochlear Implantation

An interventional study of Cochlear implant in Cochlear Hearing Loss, sponsored by Jawaharlal Institute of Postgraduate Medical Education & Research. Completed at 1 site in India. Open to participants aged 1 Year to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-24.

Sponsored by Jawaharlal Institute of Postgraduate Medical Education & Research · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
1 Year to 6 Years
Sex
All
01

Study summary

After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).This ECAP is measured intra operatively, after 4 weeks( at switch on), after 3months and 6 months following cochlear implantation.

Read the detailed description

After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).This ECAP is measured intra operatively, 4 weeks(at switch on) and after 3months and 6 months following cochlear implantation. Neural Response Telemetry (NRT) is a quick and non-invasive way of recording ECAP of the peripheral auditory nerves in-situ. It gives clinicians valuable information for programming the T- (Threshold) and C-(Comfort) - levels of the recipient's speech processor map. Intraoperative NRT in conjunction with electrode impedance data can help indicate the integrity of the implanted electrodes and the electrode/auditory nerve interface, confirming that the implant is functioning correctly intraoperatively.

02

Conditions studied

  • Cochlear Hearing Loss

Keywords

  • cochlear implant
  • threshold of electrically evoked compound action potential
  • neural response telemetry
03

In context

Hearing Loss, Sensorineural

346 studies on the registry are indexed under Hearing Loss, Sensorineural; 100 are open to participants now.

This study's enrollment of 44 is above the median of 32 across 247 interventional studies indexed under Hearing Loss, Sensorineural.

Browse Hearing Loss, Sensorineural studies →

Lead sponsor

Jawaharlal Institute of Postgraduate Medical Education & Research is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All children between 1 and 6 years of age undergoing cochlear implantation in JIPMER during the study period.

Exclusion criteria

Exclusion Criteria:

  • Incomplete electrode array insertion.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Pediatric patients with bilateral sensorineural hearing loss

    One group will be studied: Patients undergoing cochlear implantation surgery between age 1 and 6 years who meet the above inclusion and exclusion criteria seen in JIPMER during the study period.

    Device: Cochlear implant

Interventions

  • DeviceCochlear implant

    After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).

06

What researchers measure

Primary outcomes

  1. Changes in threshold of ECAP after cochlear implantation.

    To evaluate changes in threshold of ECAP during cochlear implantation, at switch on( 4 weeks), after 3 months and 6 months following cochlear implantation.

    Time frame: during implantation, at switch on( 4 weeks), after 3months and 6months.

Secondary outcomes

  1. Correlate the amplitude of ECAP with T & C levels.

    Correlating the amplitude of ECAP with threshold and comfortable levels and creating a MAP.

    Time frame: 2 years

  2. Correlate amplitude of ECAP with cochlear nerve diameter measured pre-operatively.

    By correlating amplitude of ECAP with cochlear nerve diameter we can determine the site to be operated preoperatively.

    Time frame: 2 mins

07

Study locations

1 site
  • JIPMER
    Puducherry, 605006, India
08

References and documents

Publications

  • Kim JR, Abbas PJ, Brown CJ, Etler CP, O'Brien S, Kim LS. The relationship between electrically evoked compound action potential and speech perception: a study in cochlear implant users with short electrode array. Otol Neurotol. 2010 Sep;31(7):1041-8. doi: 10.1097/MAO.0b013e3181ec1d92. PubMed 20634770 ↗
  • van Eijl RH, Buitenhuis PJ, Stegeman I, Klis SF, Grolman W. Systematic review of compound action potentials as predictors for cochlear implant performance. Laryngoscope. 2017 Feb;127(2):476-487. doi: 10.1002/lary.26154. Epub 2016 Nov 2. PubMed 27804133 ↗

Individual participant data

Plan to share: No — Confidentiality regarding patient's participation in the study will be maintained throughout the study period as well as after completion of the study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Dec 2019, 22 months.

Of 82 non-industry interventional studies with no phase under Hearing Loss, Sensorineural, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 22 months is below that.

Counting every sponsor, half of 162 studies reached it within 22 months; a quarter within 6 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2018
First posted
Apr 18, 2018
StartActual
Feb 26, 2018
Primary completionActual
Dec 31, 2019
CompletionActual
Dec 31, 2019
Last update
Feb 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03500718
Lead sponsor
Jawaharlal Institute of Postgraduate Medical Education & Research
Responsible party
Dr. Aparna Das (JUNIOR RESIDENT, Jawaharlal Institute of Postgraduate Medical Education & Research) — Principal investigator
First posted
Apr 18, 2018
Start date
Feb 26, 2018
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Feb 24, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion